[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636626":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":12,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":12,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":12,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":78,"whyStopped":12,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Efferon JSC","INDUSTRY",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Baseline therapy","NO_INTERVENTION","Patients receiving standard treatment for the treatment of thermal burns without the use of hemoadsorption methods, but who are prescribed continuous renal replacement therapy (CRRT) for renal and non-renal indications.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Baseline therapy + Efferon LPS","EXPERIMENTAL","Patients receiving standard therapy for the treatment of thermal burns, along with Efferon LPS hemoadsorption procedures in combination with continuous renal replacement therapy (CRRT).",[18],"Device: Efferon LPS",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","Efferon LPS","Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.hemoadsorption procedures, each lasting 6-12 hours, with an interval of at least 24 hours between hemoadsorption sessions (from the start of the first procedure). The procedures are performed in combination with continuous renal replacement therapy (CRRT).",[14],[26],{"name":27,"affiliation":28,"role":29},"Vladimir Kulabukhov, PhD, MD","N.V. Sklifosovsky Research Institute for Emergency Medicine","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":12,"email":35},"Alexandr Shelehov-Kravchenko, PhD, MD","CONTACT","+79636564765","ais@efferon.ru",[37],{"facility":28,"status":12,"city":38,"state":12,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Moscow","129090","Russia","RU",{"type":43,"coordinates":44},"Point",[45,46],37.61781,55.75204,{"lat":46,"lon":45},[49],{"name":27,"role":33,"phone":50,"phoneExt":12,"email":51},"+79255068081","v.kulabukhov@gmail.com",{"type":53,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100636626","efferon-lps-hemoadsorption-in-in-patients-with-thermal-burns-100636626",false,"NCT07568132","Efferon LPS Hemoadsorption in in Patients With Thermal Burns","Extracorporeal Blood Purification Using Efferon LPS Hemoadsorption in Patients With Thermal Burns: Pilot Study","Inclusion Criteria:\n\n* Thermal burns (flame, scald, or contact burns), including cases combined with inhalation injury\n* Revised Frank Index (RFI) score ≥71 and ≤181\n* Indication for extracorporeal therapy within the first 10 days after injury\n* The patient's condition allows Efferon LPS therapy to be performed for at least 6 hours\n\nExclusion Criteria:\n\n* Isolated thermal-inhalation injury\n* Chemical, electrical, or solar burns of the skin\n* Combined skin burns with frostbite and\u002For general hypothermia\n* Combined trauma (electrical injury; traumatic brain injury other than concussion or mild cerebral contusion; skull, spinal, thoracic, pelvic, or femoral fractures) or acute pre-existing pathology prior to hospital admission (acute myocardial infarction, stroke, community-acquired pneumonia, or acute surgical conditions) that may influence the course and outcome of burn disease\n* Cardiopulmonary resuscitation at the pre-hospital stage\n* End-stage renal disease\n* Acute pulmonary embolism confirmed by imaging\n* Emergency surgical treatment\n* Any other condition which, in the investigator's opinion, precludes inclusion of the patient in the study","ALL","18 Years","65 Years",{"count":65,"type":66},50,"ESTIMATED","INTERVENTIONAL",[69],"NA","The aim of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon® LPS device to reduce the severity of clinical symptoms and to prevent the progression of multiple organ dysfunction or to arrest its development in patients with burn disease with an RFI score ≥71 and ≤181.\n\nPatients will be randomized in two groups: control group receiving baseline therapy (including CRRT) and treatment group receiving baseline therapy and Efferon® LPS hemoadsorption in combination with CRRT.",[72],"Burns",[74,75,76,77],"Hemoadsorption","Hemoperfusion","Extracorporeal therapy","LPS adsorption","NOT_YET_RECRUITING","2026-04-28",{"date":81,"type":82},"2026-05-05","ACTUAL",{"date":84,"type":66},"2026-05-15",{"date":86,"type":66},"2028-02-27",{"name":5,"class":6},1]